<DOC>
	<DOCNO>NCT01189890</DOCNO>
	<brief_summary>The primary objective study determine sitagliptin treatment inferior glimepiride measure change baseline hemoglobin A1C ( HbA1C ) 30 week treatment , sitagliptin treatment result low incidence symptomatic hypoglycemia compare glimepiride . The study also evaluate sitagliptin treatment , compare glimepiride result improvement fast plasma glucose ( FPG ) level , plasma lipid level 30 week treatment . Participants randomize either sitagliptin glimepiride treatment eligibility study participation determine screen washout study phase . Participants study staff know treatment group randomize ( double-blind design ) . The duration study participation 40 week ( 9 clinic visit ) . This include screen phase ( Visit 1 Visit 2 ) 2 week maximum ; 6-week ( Visits 2 3 ) oral antihyperglycemic agent ( AHA ) wash-out phase ( take AHA prior study ) ; placebo run-in phase ( Visits 3 4 ) , follow 30 week treatment study medication .</brief_summary>
	<brief_title>Safety Efficacy Sitagliptin Compared With Glimepiride Elderly Participants With Type 2 Diabetes Mellitus ( MK-0431-251 )</brief_title>
	<detailed_description>The dose sitagliptin 100 mg daily ( QD ) 50 mg QD base participant 's estimate glomerular filtration rate ( eGFR ) . The start dose glimepiride ( 1 mg QD ) may up-titrated need optimize glycemic control first 18 week maximum dose 6 mg/day , dose increase rest study ( down-titration avoid control hypoglycemia allow ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<criteria>Inclusion Criteria Diagnosis type 2 diabetes mellitus Exclusion Criteria History type 1 diabetes mellitus Has undergone surgical procedure within prior 4 week . Current participation , participate , another study investigational device compound , prior 12 week , and/or willing refrain participate study participate study Hypersensitivity contraindication sulfonylurea ( e.g. , glimepiride ) medication Has investigational approve dipeptidyl peptidase4 ( DPP4 ) inhibitor agent ( e.g. , sitagliptin , saxagliptin ) Presence human immunodeficiency virus ( HIV ) Current participation weight loss program receive weight loss medication History blood disorder , certain cancer , heart , liver kidney disease Current past use recreational illicit drug , history drug abuse dependence , increase alcohol consumption</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Type 2 Diabetes Mellitus , Hemoglobin A1C , glucagon-like peptide 1 ( GLP-1 ) , gastric inhibitory polypeptide ( GIP ) , dipeptidyl peptidase 4 inhibitor ( DPP-4 )</keyword>
</DOC>